Stocks Health care NBIX
NASDAQ · Health careNeurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences Inc brought in $3.4B of revenue over the twelve months to June 30, 2026, up 34.4% from a year earlier. Net income was $705.5M, a net margin of 20.9%. Operating cash flow minus capital spending left $748.7M of free cash flow in fiscal 2025. At June 30, 2026 it held $332.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 31, 2026.
What Neurocrine Biosciences Inc does
Neurocrine Biosciences Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker NBIX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.9B | $478.6M | $4.67 | $748.7M |
| 2024 | $2.4B | $341.3M | $3.29 | $557.2M |
| 2023 | $1.9B | $249.7M | $2.47 | $361.6M |
| 2022 | $1.5B | $154.5M | $1.56 | $322.9M |
| 2021 | $1.1B | $89.6M | $0.92 | $233.1M |
| 2020 | $1B | $407.3M | $4.16 | $217.6M |
Latest SEC filings
What Neurocrine Biosciences Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- July 31, 2026
- July 31, 2026Exhibits 8-K/A
- July 31, 2026Quarterly report 10-Q · period to June 30, 2026
- July 30, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- May 28, 2026
- May 18, 2026
- May 18, 2026Tender offer (amended) SC TO-T/A
- May 5, 2026Quarterly report 10-Q · period to March 31, 2026
- May 5, 2026
Questions about NBIX
What does Neurocrine Biosciences Inc do?
Neurocrine Biosciences Inc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker NBIX.
Is Neurocrine Biosciences Inc profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $705.5M on revenue of $3.4B, a net margin of 20.9%.
How much revenue does Neurocrine Biosciences Inc make?
Over the twelve months to June 30, 2026 Neurocrine Biosciences Inc reported revenue of $3.4B. That is 34.4% more than a year earlier.
When did Neurocrine Biosciences Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 31, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 15, 2026.
Similar companies
Follow NBIX
Get an email when Neurocrine Biosciences Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow NBIX: get an email when it filesWhere the numbers come from
Financial figures are the values Neurocrine Biosciences Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.